Gene therapy company Orchard Therapeutics plc is making strides in the development and commercialization of hematopoietic stem cell and gene therapies. The company, headquartered in London, operates in several European nations including the UK, Italy, France, and Germany. Among its offerings are the Libmeldy brand OTL-200, a hematopoietic stem cell gene therapy aimed at treating metachromatic leukodystrophy, and Strimvelis, a gene therapy for the treatment of adenosine deaminase deficiency. Orchard Therapeutics also has bold plans in the realm of neurodegenerative disorders, including pre-clinical programs such as OTL-204 for frontotemporal dementia with progranulin mutations. The company's immunological disorder programs consist of pre-clinical programs, including a treatment for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2, and a therapy for hereditary angioedema known as OTL-105. Orchard Therapeutics plc was formerly known as Orchard Rx Limited and was founded in 2015.
Orchard Therapeutics plc's ticker is ORTX
The company's shares trade on the NASDAQ stock exchange
They are based in London, England
There are 201-500 employees working at Orchard Therapeutics plc
It is https://www.orchard-tx.com/
Orchard Therapeutics plc is in the Healthcare sector
Orchard Therapeutics plc is in the Biotechnology industry
The following five companies are Orchard Therapeutics plc's industry peers: